EGFR

Assets acting on this target.

Class
EGFR tyrosine kinase inhibitor

Epidermal growth factor receptor (EGFR) is a transmembrane protein belonging to the ErbB family of receptor tyrosine kinases. When natural ligands such as epidermal growth factor bind its extracellular domain, EGFR pairs with itself or a related receptor, activating an intracellular kinase domain that triggers signaling cascades controlling cell growth, survival, and division. In many epithelial cancers, EGFR is overactive because of gene mutation, amplification, or overexpression, driving uncontrolled proliferation. Blocking EGFR activity, either with small-molecule tyrosine kinase inhibitors that occupy the kinase's ATP-binding pocket or with antibodies that prevent ligand binding, interrupts this growth signal and can slow or halt tumor progression. Because tumors frequently acquire secondary mutations within the kinase domain that render earlier inhibitors ineffective, successive generations of EGFR-directed agents have been designed to retain potency against these resistant forms, including mutations affecting the gatekeeper residue or exon 20 insertions. EGFR-targeted therapy is most established in non-small cell lung cancer harboring activating mutations, but the target also matters in other epithelial malignancies. Because EGFR is expressed on normal epithelial tissues, particularly skin and gut lining, its inhibition characteristically produces class-related toxicities such as rash and diarrhea, an on-target consequence of blocking a pathway also needed for normal tissue maintenance.

By indication

Related mechanisms

EGFR drugs compared

42 drugs, stage by indication
42 drugs acting on EGFR: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
CetuximabEli Lilly, Merck KGaAmonoclonal antibodyApprovedApproved in Head and Neck Squamous Cell Carcinoma; Approved in Metastatic Colorectal Cancer
ErlotinibCheplapharm Arzneimittel GmbHsmall moleculeApprovedApproved in Non-Small Cell Lung Cancer; Approved in Pancreatic Cancer
GefitinibAstraZenecasmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
LazertinibJohnson & Johnson, Yuhan Corporationsmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
OsimertinibTagrissoAstraZenecasmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
SunvozertinibZegfrovyAstraZeneca, Dizal Pharmaceuticalssmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
AlmonertinibGlenmark Pharmaceuticals Ltd., Hansoh Pharmaceutical Groupsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
AndamertinibAvistone Biotechnologysmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
AsandeutertinibTYK Medicines, Inc.small moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
BecotatugShanghai JMT-Biomonoclonal antibodyPhase 3Phase 3 in Colorectal Cancer; Phase 3 in Non-Small Cell Lung Cancer
BefotertinibBetta Pharmaceuticals Co., InventisBiosmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
CPO301Conjupro Biotherapeutics, Inc.antibody-drug conjugatePhase 3Phase 3 in Breast Cancer; Phase 3 in Head and Neck Squamous Cell Carcinoma; Phase 3 in Non-Small Cell Lung Cancer
FHND9041Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Shanghai Henlius Biotechsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
FurmonertinibAllist Pharmaceuticals, ArriVent BioPharmasmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
IcotinibBetta Pharmaceuticals Co.small moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
LimertinibInnovent Biologics, Jiangsu Aosaikang Pharmaceuticalsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
PruvonertinibSuzhou Puhe Pharmaceutical Technology Co., LTDsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
RezivertinibBeta Pharma, Inc.small moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
Rilertinib (SH-1028)Nanjing Sanhome Pharmaceuticalsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
ZipalertinibCullinan Therapeutics Inc., Taiho Pharmaceuticalsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
PimurutamabShanghai Henlius Biotechmonoclonal antibodyPhase 2/3Phase 2/3 in Non-Small Cell Lung Cancer
ZorifertinibZoriferAlpha Biopharma (Jiangsu) Co., Ltd.small moleculePhase 2/3Phase 2/3 in Non-Small Cell Lung Cancer
BEBT-109BeBetter Medsmall moleculePhase 2Phase 2 in Non-Small Cell Lung Cancer
JS111Shanghai Junshi Biosciencesmall moleculePhase 2Phase 2 in Non-Small Cell Lung Cancer
SutetinibTeligene USsmall moleculePhase 2Phase 2 in Non-Small Cell Lung Cancer
ANS02Avistone Biotechnologysmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
BBT-207Parataxis Korea, Inc.small moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
BH-30643BlossomHill Therapeuticssmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
BPI-361175Betta Pharmaceuticals Co.small moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
Dositinib mesylateHenan Genuine Biotechsmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
DZD6008Dizal Pharmaceuticalssmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
H002RedCloud Biosmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
JIN-A02J Ints Biosmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
PH009-1Suzhou Puhe Pharmaceutical Technology Co., LTDsmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
SilevertinibBlack Diamond Therapeutics, Inc.small moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer; Phase 1/2 in Non-Small Cell Lung Cancer with EGFR Mutations
STX-241Pierre Fabre Medicamentsmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
VRN110755Voronoi, Incsmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
ALX2004ALX Oncology Inc.antibody-drug conjugatePhase 1Phase 1 in Non-Small Cell Lung Cancer
AST2303Allist Pharmaceuticalssmall moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer
EPI-326EpiBiologicsbispecific antibodyPhase 1Phase 1 in Non-Small Cell Lung Cancer

Showing the 40 furthest-developed of 42 drugs. The roster below lists them all, with filters.

← all mechanisms